Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma

Ashida, Atsuko; Sakaizawa, Kaori; Mikoshiba, Asuka; Kiniwa, Yukiko; Okuyama, Ryuhei

doi:10.2340/00015555-3279

Cited by 5 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atsuko et al. showed the point that ctDNA, as a useful biomarker, reflects independent impact of adverse events caused by systemic therapies for melanoma on tumor burden [32] . Further studies are needed to focus on the effect of ctDNA on the changes of condition of early stage melanoma in order to solidify our findings [29] .…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis

Feng

Cen

Tan

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

Highlight It is the first systematic review with meta-analysis assessing circulating tumor DNA as a prognostic biomarker for melanoma. Complicated and comprehensive time-to-event data had been used to perform analyses. The results showed useful tool of ctDNA detection at baseline and during follow-up, and the promising and more generally, the effectiveness of liquid biopsy. Stress the relationship between ctDNA and gene mutation.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis

Feng

Cen

Tan

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Moreover, circulating tumour necrosis factor‐α DNA copies in cfDNA correlated with the psoriasis area and severity index score in patients with severe psoriasis 5 . The concentration of plasma cfDNA levels is elevated in melanoma patients, 6 and BRAF mutation status in circulating tumour DNA (ctDNA) acts as a useful marker for disease progression of melanoma 7 …”

Section: Introductionmentioning

confidence: 99%

Genomic landscape of circulating tumour DNA in metastatic extramammary Paget’s disease

Sawamura

Myangat

Kajihara

et al. 2021

Experimental Dermatology

View full text Add to dashboard Cite

Although cancer personalized profiling by deep sequencing (CAPP‐Seq) of cell‐free DNA (cfDNA) has gained attention, the clinical utility of circulating tumour DNA (ctDNA) in extramammary Paget's disease (EMPD) has not been investigated. In this study, genomic alterations in the cfDNA and tumour tissue DNA were investigated in seven patients with metastatic EMPD. CAPP‐Seq revealed mutations in 18 genes, 11 of which have not yet been reported in EMPD. The variant allele frequency of some of the mutated genes reflected the disease course in patients with EMPD. In one patient, the mutation was detected even though imaging findings revealed no metastasis. In another patient with triple EMPD (genital area and both axilla), cfDNA sequencing detected the mutation in a rib metastatic lesion, which was also detected in both axilla lesions but not the genital region. Investigations of the ctDNA may be useful towards the elucidation of clonal evolution in EMPD.

show abstract

“…However, LDH also re ects side effect of drugs and infection, thus it may not become an accurate biomarker that correlates with disease status. Liquid biopsy, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and circulating microRNA, have attracted attention as potential biomarkers [5][6][7]. ctDNA, which is released from dead tumor cells, is present in peripheral blood as cell-free DNA and is a useful tool for monitoring real-time disease status.…”

Section: Introductionmentioning

confidence: 99%

Usefulness of Monitoring Circulating Tumor Cells as a Therapeutic Biomarker in Melanoma with BRAF Mutation

Okuyama

Kiniwa

Nakamura

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Circulating tumor cells (CTCs) are non-invasive biomarkers that could be used to characterize changes in tumors. In this study, we monitored the number of CTCs, as well as the BRAF genotype of individual CTCs. Methods: CTCs were isolated from peripheral blood using a high-density dielectrophoretic microwell array, followed by labeling with melanoma-specific markers (MART-1 and/or gp100) and a leukocyte marker (CD45). Results: Examination of patients with stage 0–III melanoma detected CTCs even in patients with early disease (stage 0 or I). Next, we analyzed CTCs in five patients with stage IV melanoma during treatment with BRAF/MEK inhibitors. The number of CTCs fluctuated in association with the drug response in four of the five patients, suggesting that the total number of CTCs usually reflected the drug response. Interestingly, one of those patients had CTCs with seven different BRAF genotypes, and the mutated CTCs disappeared upon treatment with BRAF/MEK inhibitors, except for those harboring BRAFA598V.Conclusions: CTCs are present even in the early stage of melanoma, and the number of CTCs seems to reflect drug response during treatment with BRAF/MEK inhibitors. Furthermore, genetic heterogeneity of BRAF may contribute to drug resistance of BRAF/MEK inhibitor. Our findings demonstrate the usefulness of CTC analysis in melanoma for monitoring targeted therapies and understanding mechanism of drug resistance.

show abstract

Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma

Cited by 5 publications

References 9 publications

The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis

The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis

Genomic landscape of circulating tumour DNA in metastatic extramammary Paget’s disease

Usefulness of Monitoring Circulating Tumor Cells as a Therapeutic Biomarker in Melanoma with BRAF Mutation

Contact Info

Product

Resources

About